Antibiotic-loaded nanomesh developed for drug delivery
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
Browsing: Treatments
SEA-PHAGES: from educational project to treatment prospect – an interview with Graham Hatfull
Graham Hatfull speaks about heading up the SEA-PHAGES project and the role this has played in understanding phage diversity and evolution, in addition to commenting on a recent case where a phage cocktail was used to treat a case of Mycobacterium abscessus.
Two Ebola treatments prove effective in DRC outbreak
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Gaming infectious diseases – an interview with Salam Abbara
Could board games be used as an educational tool to help teach and raise awareness around some of the major challenges in infectious diseases? In this interview we speak to Salam Abbara about the game she has helped develop, which aims to help medical students learn and understand antibiotic prescribing.
Modulating arbovirus infection via mosquito saliva – an interview with Daniella Lefteri
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
A peek behind the paper – Andrew Brooks on ethnicity-associated microbiomes and personalized therapies
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘How could ethnicity-associated microbiomes contribute to personalized therapies?’, as we ask the authors about the factors that influence the microbiome composition, how these could be manipulated and the future of this field.
Supplements of Akkermansia muciniphila could reduce cardiovascular risk factors
Intestinal bacteria, Akkermansia muciniphila, could limit the increase of cardiovascular risk factors according to findings from the first in-human study.
Fecal Microbial Transplant: FDA warns about the risk of transferring multidrug-resistant organisms
The US FDA has issued a safety communication regarding investigational FMT, warning that there is a risk of serious infection caused by the transfer of multidrug-resistant organisms.
The ASPECT-NP study, rationale, results and repercussions – an interview with Igancio Martin-Loeches and Marin Kollef
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
A peek behind the paper – Nuno Cerca on combating bacterial vaginosis
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.
